Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
about
Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinomaRecent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop MechanismSorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceDiscovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsMultikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression.Evaluation of artemisinins for the treatment of acute myeloid leukemia.Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias.Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft modelMolecular therapeutic approaches for pediatric acute myeloid leukemia.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.NFATc1 as a therapeutic target in FLT3-ITD-positive AML.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
P2860
Q28239708-B0F4A82D-4A51-4E19-8EA8-01F1FC10FC26Q28535006-A530B9A9-4D73-4166-AB08-8598B6105CA7Q33618658-4CF8E775-DD87-4C81-9E81-A6298E9691D0Q33633267-A685581F-ECFB-43A2-97BB-1B8704B492DAQ34656484-00E3DB30-C35F-4596-B5E4-F20E804BE82BQ34689078-85719614-9903-404C-98D5-0148A4649E06Q34774854-833030E6-2476-423F-BA93-AEAD4D0E052FQ34975439-1468D875-9FD1-44D1-93D8-FB9CB7E0378CQ35172210-5D3B17C0-146A-4DA5-9634-180A9BEB1897Q36237312-8DB1452B-D478-4189-BF44-A16D07DB0B5DQ36463168-E47C90C0-1092-4EC5-AFBD-AA939566B4E4Q36544596-C559BD62-2DDC-4AF1-8953-3641102414F2Q36998913-228578CA-5D24-402C-8D2E-396A6FFF21DAQ37033027-74D98F09-2633-4369-8014-DC33016BE854Q37334711-263B0594-3450-4A8D-B425-2EAE0DE020AEQ37379676-B46A4DA9-437D-4E5A-870F-16E1578222F4Q37594395-A686FADC-5FF9-49BB-AA51-F6DCA7C184C6Q37598626-BCA3BCB8-B841-4370-BC2F-4AE25CF7A64DQ37640370-E0A4FFE6-4018-4EF9-8AD7-C94AAFABC3CCQ37643136-A635EB49-478F-4DA7-8262-E526679EC3B0Q38061500-509910D9-38C8-4CF7-8CBC-001EAD7D8611Q38201503-247F2545-6222-4B28-8134-A141839A5BC0Q38336723-FFF65C30-96B0-4640-BE8B-577B8E5F4FE2Q40937224-70481DFE-9C82-4738-B0C0-FC3F46AD4718Q41763725-B212BFD1-117E-43B8-85EC-1CAE4614EC51Q46931556-62131D7A-3290-42FA-938E-11951792647FQ51134492-8CF169F0-6CEF-474F-9066-7F15D790DB3EQ54252958-EE306C9B-8868-4697-BAF4-CB9265119ACC
P2860
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@ast
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@en
type
label
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@ast
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@en
prefLabel
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@ast
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@en
P2093
P2860
P356
P1476
Activity of the multikinase in ...... ine in acute myeloid leukemia.
@en
P2093
Charles Rose
Christopher Calabrese
Dario Campana
Hiroto Inaba
Hongmei Niu
Jeffrey E Rubnitz
Jerold E Rehg
John C Panetta
Sharyn D Baker
Shelley Orwick
P2860
P304
P356
10.1093/JNCI/DJR107
P407
P577
2011-04-12T00:00:00Z